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Role of polymorphisms of the endothelial nitric oxide synthase
gene in predicting slow-flow phenomenon after primary
percutaneous coronary intervention
Primer perkütan koroner girişim sonrası yavaş akım fenomeninin öngörülmesinde 
endotelyal nitrik oksit sentaz geni polimorfizmlerinin rolü
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Objective: The aim of the present study was to examine 
the association between 2 polymorphisms of the endothelial 
nitric oxide (eNOS) gene (-786T>C and +894G>T) and the 
no-reflow/slow-flow phenomenon in post-primary percuta-
neous coronary intervention (PPCI) patients.
Methods: A total of 103 post-PPCI patients were enrolled. 
Coronary no-reflow phenomenon was defined as a Throm-
bolysis in Myocardial Infarction (TIMI) flow grade 0–1 and 
coronary slow-flow phenomenon (CSFP) was defined as a 
TIMI flow grade ≤2. 
Results: Due to the small number of post-PPCI patients with 
the no-reflow phenomenon (n=4), the primary comparison 
was made between CSFP (n=20) and normal flow (n=83) 
groups. There was a greater frequency of CSFP among 
carriers of the –786C allele of the eNOS –786T>C polymor-
phism (odds ratio [OR]: 3.90; 95% confidence interval [CI]: 
0.87–17.45; p=0.07). However, no such association was 
detected between the +894T allele of the eNOS +894G>T 
and CSFP (OR: 0.92; 95% CI: 0.21–3.98; p=0.91). In the 
adjusted analysis, the -786T>C polymorphism did not reach 
statistical significance.
Conclusion: There was no significant association between 
CSFP and 2 of the most common polymorphisms of the 
eNOS gene in post-PPCI patients.
Amaç: Bu çalışmada, primer perkütan koroner girişim (PPKG) 
yapılan hastalarda endotelyal nitrik oksit (eNOS) geninin 
(-786T>C ve +894G>T) iki polimorfizmi ile akımsızlık /yavaş 
akım fenomeninin ilişkisini araştırmayı amaçladık.
Yöntemler: PPKG sonrası toplam 103 hasta çalışmaya 
dahil edildi. Koroner akımsızlık fenomeni miyokart enfark-
tüsünde tromboliz (TIMI) akım derecesi 0–1, koroner yavaş 
akım fenomeni (KYAF) ise TIMI akım derecesi ≤2 olarak ta-
nımlandı.
Bulgular: PPKG sonrasında akımsızlık gelişen hasta sayı-
sının azlığı (n=4) nedeniyle, ana karşılaştırma KYAF (n=20) 
ve normal akım (n=83) grupları arasında yapıldı. eNOS 
–786T>C polimorfizminin –786C aleli taşıyıcıları, daha yüksek 
sıklıkta KYAF’a sahip olma eğilimi gösterdi (OR: 3.90, %95 
GA: 0.87–17.45; p=0.07). Bununla birlikte, eNOS +894G>T 
ve KYAF’nin +894T aleli için böyle bir ilişki saptanmadı (OR: 
0.92, %95 GA: 0.21–3.98; p=0.91). Düzeltilmiş analizde, ayar-
lamalar yapıldıktan sonra -786T> C polimorfizmi istatistiksel 
öneme ulaşmadı.
Sonuç: PPKG sonrası hastalarımızda KYAF ile eNOS geni-
nin en sık görülen polimorfizmlerinden ikisi arasında anlamlı 
bir ilişki bulamadık.
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Acute ST-segment elevation myocardial infarction (STEMI) is most often caused by the throm-
botic occlusion of an epicardial coronary artery.[1–3] 
Primary percutaneous coronary intervention (PPCI) 
is currently the preferred treatment strategy for pa-
tients with STEMI in that it can successfully reopen 
the occluded vessel in more than 95% of cases.[1] In-
terestingly, even when the mechanical obstruction is 
corrected, the flow will not be adequately restored in a 
significant number of patients. This condition, termed 
no-reflow phenomenon, may occur in up to 40% of 
post-PPCI patients. No-reflow phenomenon is consid-
ered a significant independent predictor of in-hospital 
mortality, major adverse cardiac events, and malig-
nant arrhythmias, and can, thus, lessen the beneficial 
impact of PPCI.[1 3–6]
Given the abovementioned important prognostic 
effects of the no-reflow phenomenon, multiple inves-
tigations have tried to determine potential predictors. 
Demographic characteristics (e.g., age and gender),[7] 
clinical presentation,[8–11] the presence of traditional 
coronary risk factors, laboratory findings (e.g., hy-
perglycemia[12] and hematological indices[13]), angio-
graphic properties (e.g., thrombus grade[14] and the 
SYNTAX score[15]), and procedural factors (e.g., the 
use of post-dilation[16] and long stenting[17]) have all 
been considered as potential candidates for predicting 
the risk of diminished flow after PPCI.
In addition, attempts have been made to find 
molecular or genetic predictors of the pathophysiol-
ogy of STEMI. The pathophysiology of the no-reflow 
phenomenon is complex and multifactorial insofar 
as such mechanisms as platelet activation, distal em-
bolization, coronary spasm, reperfusion injury, and 
localized inflammation lead to endothelial dysfunc-
tion,[17–19] and hence, diminish vasodilation and create 
microvascular flow impairment.[20,21] Normally, the 
healthy endothelium regulates vascular tone via the 
release of nitric oxide (NO).[22] NO serves to relax the 
vascular smooth muscle, to inhibit platelet activation 
and leukocyte adhesion, and to modulate the migra-
tion and growth of vascular smooth muscle cells.[4,5] 
Consequently, alterations in the NO pathway and its 
enzyme, endothelial nitric oxide synthase (eNOS), 
may cause endothelial dysfunction.[5]
Several polymorphisms have been discovered in 
the eNOS gene. Two common variants, a variant with 
a T/C substitution in the 5′ flanking region near the 
promoter at position 
−786 and a variant 
with a G/T substitu-
tion at position 894 
in exon 7 that codes 
for the replacement 
of glutamic acid with 
aspartic acid, have 
been linked by sev-
eral groups of inves-
tigators to the risk 
of coronary spasm, 
coronary artery dis-
ease (CAD), and 
acute myocardial in-
farction (MI).[22–25] 
Therefore, functionally important polymorphisms 
of the eNOS gene might be related to individual dif-
ferences in susceptibility to ischemic injury during 
STEMI and explain the diverse prevalence of the no-
reflow phenomenon.[5]
The aim of the present study was to demonstrate 
the correlation between the occurrence of the no-re-
flow/slow-flow phenomenon in post-PPCI patients 
and polymorphisms of the eNOS gene and to compare 
it with other suggested predisposing factors. 
METHODS
Study design
Between August 2017 and September 2018, all pa-
tients with acute STEMI who were candidates for 
PPCI at Rajaie Cardiovascular Medical and Research 
Center were enrolled in this single-center, prospec-
tive, cross-sectional study. The diagnosis of STEMI 
was made according to the Third Universal Defini-
tion of Myocardial Infarction.[26] The exclusion crite-
ria were age <18 years, allergy to the contrast agent, 
unsuccessful PPCI, and previous revascularization 
(i.e., coronary bypass graft surgery or PCI). Written 
informed consent was obtained from all the patients 
before blood sampling, and the study protocol was ap-
proved by the Ethics Committee of Rajaie Cardiovas-
cular Medical and Research Center (ethics approval 
number: 94015).
Blood samples, collected just before the start of 
the PCI procedure, were used to analyze biochemi-
cal parameters, hematological indices, and cardiac 
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biomarkers through standard methods. For the ge-
netic analysis, 2 cc of each sample was kept at -20°C. 
Fasting blood glucose levels and lipid profiles were 
recorded using a sample collected on the postproce-
dural day. 
All of the patients had received combined an-
tiplatelet therapy with loading doses of 325 mg of 
aspirin and 600 mg of clopidogrel at the time of the 
diagnosis of STEMI. PPCI was performed according 
to the latest standard guidelines.[27] At the beginning 
of the procedure, a weight-based loading dose of un-
fractionated heparin was injected intravenously and 
complementary doses were administered according 
to the activated clotting time during the procedure. 
The use of glycoprotein IIb/IIIa inhibitors, aspiration 
thrombectomy, and pre- or post-dilation was at the 
discretion of the operator. 
The coronary angiograms were evaluated by 2 expe-
rienced interventional cardiologists, who were blinded 
to the patients’ clinical data. The coronary blood flow 
patterns were assessed based on the Thrombolysis in 
Myocardial Infarction (TIMI) flow grade, immediately 
before and after PPCI. The TIMI grade was classified 
as follows: grade 0, no perfusion; grade 1, presenta-
tion without perfusion; grade 2, partial perfusion; and 
grade 3, complete perfusion.[28] No-reflow phenome-
non was defined as a TIMI flow grade 0–1, and coro-
nary slow-flow phenomenon (CSFP) was defined as 
a TIMI flow grade ≤2.[29] Mechanical complications, 
such as coronary dissection and spasm, were excluded 
from the analysis. The SYNTAX score was calculated 
using the online calculator (http://www.syntaxscore.
com). Thereafter, the patients were categorized into 
tertiles based on the calculated SYNTAX scores: low 
(<23), intermediate,[23–32] and high (>32).[30]
The thrombus grade was evaluated using the TIMI 
thrombus scale: grade 0, no angiographic sign of 
thrombi was detected; grade 1, possible angiographic 
characteristics of thrombi, such as decreased contrast 
density, haziness, and irregular lesion contours ob-
served; grade 2, a definite thrombus ≤1/2 the vessel 
diameter; grade 3, the largest dimension of the throm-
bus was >1/2 but <2 the vessel diameter; grade 4, the 
thrombus was >2 the vessel diameter; grade 5, total 
occlusion.[31] The TIMI thrombus grades were cate-
gorized as high (grades 4 and 5) and low thrombus 
grades (grades 1–3). 
The CHA2DS2-VASc score was calculated ac-
cording to the points assigned to each of the risk 
predictors: congestive heart failure (1 point); hyper-
tension (1 point); age ≥75 years (2 points); diabetes 
mellitus (1 point); previous stroke, transient ischemic 
attack, or thromboembolism (2 points); vascular dis-
eases (i.e., history of MI, peripheral arterial disease, 
or complex aortic plaques) (1 point); age between 65 
and 74 years (1 point); and female gender (1 point). 
Determination of the polymorphisms of the
eNOS gene
For the purposes of DNA extraction, 200 µL of blood 
from each of a total of 119 patients was collected 
in tubes containing pre ethylenediaminetetraacetic 
acid (0.4 M at pH 8.0). The GF-1 Blood DNA Ex-
traction Kit (Vivantis Technologies, Shah Alam, 
Selangor Darul Ehsan, Malaysia) was used, and 
genomic DNA was isolated according to the com-
pany’s manual. The 894G>T and -786T>C mutations 
in the eNOS gene were analyzed using polymerase 
chain reaction (PCR), followed by restriction frag-
ment length polymorphism (RFLP). The amplifica-
tion of 894G>T was completed using forward primer 
5’-TCCCTGAGGAGGGCATGAGGCT-3’ and re-
verse primer 5’-TGAGGGTCACACAGGTTCCT 
-3’.[32] The amplification of -786T>C 
was performed using forward primer 
5’-AGTTTCCCTAGTCCCCCATGC-3’ and reverse 
primer 5’-CCACACCCCCATGACTCAAGT-3’.[33] 
PCR was performed in a total volume of 30 μL con-
taining 100 ng of genomic DNA, 25 mM of magne-
sium chloride, 500 µM of each of deoxynucleoside 
triphosphates, and 1 U of Taq DNA polymerase. With 
respect to the PCR conditions, the amplification of 
894G>T began with an initial denaturation at 95°C for 
1 minute, 35 cycles at 94°C for 1 minute, 61°C for 1 
minute (annealing), and 72°C for 1 minute, followed 
by a final extension at 72°C for 7 minutes. The ampli-
fication of -786T>C was performed with an initial de-
naturation at 94°C for 1 minute, 30 cycles at 94°C for 
45 seconds, 61°C for 1 minute (annealing), and 72°C 
for 1 minute, followed by a final extension at 72°C 
for 7 minutes. The Ban II restriction enzyme (New 
England Biolabs, Inc., Ipswich, MA, USA) was used 
at 37°C for 20 hours for 894G>T, while the NgoMIV 
restriction enzyme (New England Biolabs, Inc., Ip-
swich, MA, USA) was used at 37°C for 2 hours for 
-786T>C. The PCR and RFLP products were visual-
ized on 12.5% polyacrylamide electrophoresed gel.
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Determinants of the patients’ clinical presentation 
(i.e., blood pressure and heart rate on admission, dura-
tion of chest pain, and Killip class) were fairly similar 
between the 2 groups (Table 1). 
The level of blood sugar on admission in the CSFP 
group was significantly higher than that of the NF 
group (median: 200.00 mg/dL [min-max: 136.00–
293.00 mg/dL] vs median: 137.00 mg/dL [min-max: 
116.50–170.50 mg/dL]; p=0.02). All hematological 
indices studied in previous reports (i.e., white blood 
cell, neutrophil, lymphocyte, and platelet counts 
together with the lymphocyte/platelet ratio) were 
analyzed in the present study as well: The results 
demonstrated that none was statistically significantly 
different between the 2 study groups except hemo-
globin (mean: 13.70±1.50 g/dL in the CSFP group 
vs mean: 14.40±1.50 g/dL in the NF group; p=0.04). 
The platelet count was marginally higher in the CSFP 
group than in the NF group (median: 250,000.00 [min-
max: 198,500.00–282,000.00] vs median: 226,500.00 
[min-max: 204,000.00–249,250.00]; p=0.07).
The angiographic characteristics of the patients are 
summarized in Table 2, which shows that 43 (41.7%) 
patients had single-vessel disease, 35 (33.9%) double-
vessel disease, and 25 (24.3%) triple-vessel disease. 
The culprit artery was the left anterior descending in 
47 (45.6%) patients, the right coronary artery in 34 
(33.0%), and the left circumflex artery in 6 (5.8%). 
Additionally, 16 (15.5%) patients had thrombotic le-
sions in the obtuse marginal, diagonal branches, or the 
ramus intermedius. No clear difference was detected 
between the 2 groups regarding vessel involvement. 
The mid-portion of the vessel was the most commonly 
affected site (53 [51.5%] patients). The proportion of 
the distal involvement of the coronary vasculature in 
the CSFP group was significantly higher than that of 
the NF group (20.0% vs 4.8%; p=0.03). The thrombus 
grade and high thrombus grade (thrombus grade >3) 
findings during the diagnostic angiography in the cul-
prit vessel were similar between the 2 study groups.
The mean SYNTAX score was 16.67±6.74 in the 
CSFP group and 15.90±8.27 in the NF group. Neither 
the SYNTAX score nor the SYNTAX category was 
significantly different between the 2 groups. 
Among the procedural factors (Table 3), the mean 
door-to-balloon time was similar between the CSFP 
and NF groups (median: 27.50 minutes [min-max: 
Statistical analysis 
Deviations from the Hardy-Weinberg equilibrium for 
each single-nucleotide polymorphism (SNP) were de-
termined using chi-square analysis with 1 degree of 
freedom. The sample size was calculated according to 
a previous study published by our center.[8] The quan-
titative data were described as the mean±SD for nor-
mally distributed data based on the Shapiro-Wilk test, 
while the non-normal variables were presented as the 
median (interquartile ranges: P25–P75). The between-
group differences were analyzed using the Student’s 
t-test and the Mann-Whitney U test, where indicated. 
The categorical data were expressed as percentages and 
were tested using a chi-square test and the Fisher exact 
test was used in the event of small expected cell counts.
Binary logistic regression was employed to de-
termine the effects of various factors on CSFP. The 
selection process of the variables in the multivariate 
logistic modeling was performed in accordance with 
the Hosmer-Lemeshow guideline.[34] The odds ratio 
(OR) of the adjusted predictors for CSFP in 894G>T 
was not calculated because of the higher p value of 
unadjusted 894G>T.
All p values were 2-tailed, and a p value <0.05 
was considered statistically significant. The statistical 
analyses were performed using Stata version 14 soft-
ware (StataCorp LLC, College Station, TX, USA).
RESULTS
Between August 2017 and September 2018, the 
present study recruited 119 patients, of whom 16 in-
dividuals were excluded due to inadequate DNA ex-
traction. Due to the small number of patients with the 
no-reflow phenomenon, the primary analysis was con-
ducted between patients with CSFP (TIMI flow grade 
≤2) and those with normal flow (NF) after PPCI. The 
demographic and clinical characteristics of the study 
population are depicted in Table 1. There were no sig-
nificant differences between the groups in terms of 
age, gender, or diabetes mellitus. A history of diabetes 
mellitus was present in 21.4% of the study population.
In terms of the traditional coronary risk factors, 
there were no statistically significant differences be-
tween the CSFP and NF groups concerning hyperten-
sion or a family history of CAD (Table 1). Cigarette 
smoking was significantly less frequent in the CSFP 
group than in the NF group (30.0% vs 54.2%; p=0.05). 
21.25–33.75 minutes] vs median: 25.00 minutes 
[min-max: 20.00–30.00 minutes]; p=0.51). There 
were no statistically significant differences between 
the 2 groups with respect to the stent length (median: 
29.00 mm [min-max: 18.50–35.25 mm] vs median: 
24.00 mm [min-max: 18.00–30.00 mm]; p=0.14), or 
the stent diameter (median: 3.00 mm [min-max: 2.75–
3.37] vs median: 3.00 [min-max: 2.75–3.50]; p=0.23). 
As previously explained, the use of pre- and post-di-
lation was left to the operator’s discretion: 41 (39.8%) 
patients had pre-dilation and 13 (12.7%) post-dilation. 
Neither was related to the post-PCI TIMI flow. 
Table 1. Baseline demographic, clinical, and laboratory characteristics of the patients
Variable Total sample Normal-flow group Slow-flow group Normal flow 
  (n=103) (n=83) (n=20) vs slow flow
     p value
Age (years)  58.14±12.37 57.14±12.23 62.30±12.38 0.09
Female  17 (16.5) 12 (14.5) 5 (25.0) 0.26
Diabetes mellitus  22 (21.4) 16 (19.3) 6 (30.0) 0.29
Traditional risk factors 
 Hypertension 38 (36.9) 30 (36.1) 8 (40.0) 0.74
 Cigarette smoking 51 (49.5) 45 (54.2) 6 (30.0) 0.05
 Family history 16 (15.5) 13 (15.7) 3 (15.0) 0.90
Clinical state on arrival
 Blood pressure 130.18±29.68 131.44±31.10 124.95±22.80 0.47
 Heart rate 80.70±17.27 81.06±17.04 79.25±18.61 0.67
 Killip II class at admission >1 17 (16.5) 12 (14.5) 5 (25.0) 0.25
 Chest pain duration (hours)  3.00 (2.00–5.00) 3.00 (2.00–5.00) 4.00 (2.50–4.75) 0.52
CHA2DS2-VASc score >2 49 (47.6) 37 (44.6) 12 (60.0) 0.21
CHA2DS2-VASc score 1.00 (1.00–2.00) 1.00 (1.00–2.00) 2.00 (1.00–2.00) 0.37
Left ventricular ejection fraction  37.08±9.67 37.01±9.65 37.36±10.05 0.88
Blood sugar on admission 142.00 137.00 200.00 0.02
  (117.25–199.00) (116.50–170.50) (136.00–293.00)
Fasting blood sugar (mg/dL) 119.00 118.50 122.50 0.64
  (105.00–156.5.00) (104.25–155.50) (106.50–158.25)
Hemoglobin (g/dL) 14.21±1.98 14.45±1.50 13.21±3.17 0.04
Total cholesterol (mg/dL) 171.23±41.15 171.32±39.64 170.80±49.51 0.96
Low-density lipoprotein (mg/dL) 108.00 (78.00–127.00) 108.50 (79.50–125.25) 92.00 (65.00–130.00) 0.70
Triglyceride (mg/dL) 127.00 (88.00–171.5) 128.50 (86.75–170) 127 (94–215) 0.77
High-density lipoprotein (mg/dL) 38.00 (35.00–45.00) 37.50 (34.50–45.00) 39.00 (36.00–47.00) 0.43
Cr (mg/dL) 0.90 (0.80–1.00) 0.90 (0.80–1.00) 0.90 (0.80–1.22) 0.71
Blood urea nitrogen (mg/dL) 15.00 (12.50–20.00) 15.00 (12.50–19.00) 15.50 (12.25–21.00) 0.79
White blood cell 10600.00 10600.00 10750.00 0.76
  (8775.00–10600.00) (8775.00–12425.00) (8725.00–13007.50)
Neutrophilic count 8136.28±2841.15 8080.23±2663.24 8366.07±3550.04 0.68
Platelet count 232500.00 226500.00 250000.00 0.076
  (204000.00–261250.00) (204000.00–249250.00) (198500.00–282000.00)
Platelet/lymphocyte 12834.82 12834.82 12903.51 0.50
  (9215.27–18484.61) (9018.29–18316.66) (9354.16–22123.62)
Data are presented as number (%), mean±SD or median (minimum-maximum).
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the groups concerning the genotypes of the 894G>T 
polymorphism (Table 4). In this polymorphism, the 
patients with G/G were considered the reference 
group (Table 5). In comparison with the G/G group, 
the OR of CSFP was 0.92 for patients with T/T, which 
was nonsignificant (95% CI: 0.21–3.98; p=0.91), and 
the OR of CSFP for patients with 894G>T was 0.62, 
which did not constitute statistical significance (95% 
CI: 0.21–1.82; p=0.39). As was previously clarified, 
the adjusted analysis was performed only for -786T>C 
due to the higher p value of unadjusted 894G>T. After 
adjustments, -786T>C was not a significant predictor 
of CSFP following PPCI (Table 5).
Table 6 reports the adjusted and unadjusted effects 
of potential clinical predictors of CSFP after PPCI. 
In multivariate analysis, the platelet count, the blood 
sugar level on admission, and the hemoglobin level 
failed to reach statistical significance after adjustments.
Both SNPs (-786T>C and 894G>T) satisfied the 
Hardy-Weinberg equilibrium.
The genotype frequency (Table 4) of the -786T>C 
polymorphism for T/T, T/C, and C/C was 47 (45.6%), 
45 (43.7%), and 11 (10.7%), respectively, in the en-
tire study population. There was no statistically sig-
nificant relationship between the groups regarding the 
-786T>C genotype. The patients with the T/T geno-
type were regarded as the reference group (Table 5). 
In comparison with the T/T group, the OR of CSFP 
was 1.95 for patients with T/C (95% CI: 0.64–5.91; 
p=0.23) and 3.90 for patients with C/C (95% CI: 0.8–
17.45; p=0.07) (Table 5). 
The genotype distribution (Table 4) of the 894G>T 
polymorphism for G/G, G/T, and T/T was 44 (42.7%), 
45 (43.7%), 14 (13.6%), respectively, in the entire 
study population. As in the -786T>C variant, there 
was no statistically significant relationship between 
Table 2. Angiographic characteristics of the patients
Angiographic characteristic Total sample Normal-flow group Slow-flow group p value
  (n=103) (n=83) (n=20)
Number of diseased vessels (%)  
 Single-vessel disease 43 (41.7) 35 (42.2) 8 (40) 0.43
 Two-vessel disease 35 (33.9) 26 (31.3) 9 (45)
 Three-vessel disease 25 (24.3) 22 (26.4) 3 (15) 
Culprit (%)
 Left anterior descending artery 47 (45.6) 38 (45.8) 9 (45) 0.90
 Left circumflex coronary artery 6 (5.8) 5 (6) 1 (5) 
 Right coronary artery 34 (33) 27 (32.5) 7 (35)
 Obtuse marginal, diagonal 16 (15.5) 13 (15.6) 3 (15)
 branches, ramus intermedius, 
 posterior left ventricle 
Location (%)
 Proximal 42 (40.8) 37 (44.6) 5 (25) 0.03
 Mid-portion 53 (51.5) 42 (50.6) 11 (55)
 Distal 8 (7.8) 4 (4.8) 4 (20)
Thrombus grade (%)
 ≤3 18 (17.5) 14 (16.9) 4 (20) 0.74
 4 and 5 85 (82.5) 69 (83.1) 16 (80)
SYNTAX score (mean±SD) 16.05±7.97 15.90±8.27  16.67±6.74 0.45
SYNTAX category (%)
 Low 81 (78.6) 66 (79.5) 15 (75) 0.65
 Intermediate 19 (18.4) 14 (16.9) 5 (25)
 High 3 (2.9) 3 (3.6) 0 (0)
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occurrence of the no-reflow phenomenon following 
PPCI. We also compared prognostic efficacy of these 
gene polymorphisms and other previously suggested 
predisposing factors. Although multiple studies have 
DISCUSSION
In the present study, we sought to investigate the value 
of the polymorphisms of the eNOS gene in predicting 
Table 4. Genotype and allele frequency of +894G>T and -786T>C  polymorphisms of the eNOS gene
  Total sample Normal-flow group Slow-flow group p value
  (n=103) (n=83) (n=20)
+894G>T polymorphism, n (%)   
 G/G 44 (42.7) 34 (41) 10 (50) 0.67
 G/T 45 (43.7) 38 (45.8) 7 (35) 
 T/T 14 (13.6) 11 (13.3) 3 (15) 
Allele   
 G 133 (64.6) 106 (63.85) 27 (67.5) 0.46
 T 73 (35.4) 60 (36.14) 13 (32.5) 
-786T>C polymorphism, n (%)   
 T/T 47 (45.6) 41 (49.4) 6 (30) 0.16
 T/C 45 (43.7) 35 (42.2) 10 (50) 
 C/C 11 (10.7) 7 (8.4) 4 (20) 
Allele, n (%)    
 T 139 (67.5) 117 (70.48) 22 (55) 0.11
 C 67 (32.5) 49 (29.51) 18 (45)
eNOS: Endothelial nitric oxide synthase.
Table 3. Procedural characteristics of the patients
Procedural characteristic of PCI Total sample Normal-flow group Slow-flow group p value
  (n=103) (n=83) (n=20)
Door-to-balloon time (minutes) 25.00 (20.00–30.00) 25.00 (20.00–30.00) 27.50 (21.25–33.75) 0.51
Stent length (mm)  25.00 (18.00–32.00) 24.00 (18.00–30.00) 29.00 (18.50–35.25) 0.14
Stent diameter (mm)  3.00 (2.75–3.50) 3.00 (2.75–3.50) 3.00 (2.75–3.37) 0.23
Pre-dilation 41 (39.8) 31 (37.3) 10 (50) 0.30
Post-dilation 13 (12.7) 13 (15.9) 0 (0) 0.05
Pre-PCI TIMI flow
 TIMI 0  82 (79.6) 67 (80.7) 15 (75) 0.78
 TIMI 1 7 (6.8) 5 (6) 2 (10)
 TIMI 2 3 (2.9) 2 (2.4) 1 (5)
 TIMI 3 11 (10.7) 9 (10.8) 2 (10) 
Post-PCI TIMI flow
 TIMI 1 4 (3.9)  4 (20) <0.001
 TIMI 2 16 (15.5)  16 (80)
 TIMI 3 83 (80.6) 83 (100)
 TIMI<3 103 (100)  20 (100)
PCI: Percutaneous coronary intervention; TIMI: Thrombolysis in Myocardial Infarction.
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adhesion and to modulate the growth of the vascular 
smooth muscle.[4,40] 
Previous studies have indicated that NOS3 poly-
morphisms can affect both the production and the 
function of NO and may cause endothelial dysfunc-
tion.[29,41,42] Therefore, polymorphisms of the eNOS 
gene are considered to be a risk factor for this phenom-
enon.[43] Hingorani et al.[40] were the first investigators 
to observe that a point G/T mutation in exon 7 of the 
NOS3 polymorphism (894G>T) was correlated with 
CAD and recent MI. Ensuing investigations revealed 
that the mentioned SNP might be related to the occur-
rence of MI,[44] the increased risk of coronary spasm,[25] 
and the incidence of essential hypertension.[45] Subse-
quent studies reported mixed results about the role of 
the 894G>T polymorphism in CAD inasmuch as some 
investigations allied the SNP to a lower intracellular 
NO production rate,[45,46] whereas others rejected any 
relationship.[47] The same situation exists for the other 
common NOS gene variant, -786T>C. In their early 
report, Nakayama et al.[48] demonstrated that the SNP 
evaluated the role of genetic predisposing factors in 
the occurrence of CSFP,[29,35–37] there are limited data 
on their role in a setting of STEMI. 
The no-reflow phenomenon is a feared complica-
tion after PPCI; it is associated with a poor long-term 
prognosis and is regarded as an independent predictor 
of death, MI, and impaired left ventricular function.[38] 
Various treatments have been tested for the no-reflow 
phenomenon; however, the complex and multifacto-
rial pathogenesis of this phenomenon limits the effi-
cacy of these therapies.[14,39] Hence, it is essential that 
patients at higher risk of the no-reflow phenomenon 
be identified and treated early. In this regard, several 
studies have demonstrated that biomarkers and other 
clinical parameters could be helpful in the risk assess-
ment and identification of high-risk patients.[11] 
Endothelial dysfunction may play a key role in the 
pathophysiology of the no-reflow phenomenon. NO is 
synthesized by eNOS and has a regulatory function in 
vasomotor tone and blood flow.[4] Endothelial NO has 
the ability to inhibit platelet activation and leukocyte 
Table 5. Adjusted and unadjusted effects of the +894G>T and -786T>C polymorphisms of the eNOS gene as predictors 
of the coronary slow-flow phenomenon after primary PCI
 Unadjusted Adjusted*
Genotype Reference group OR (95% CI) p value OR (95% CI) p value
–786T>C  polymorphism     
 C/C T/T 3.90 (0.87–17.45) 0.07 3.54 (0.49–25.21) 0.20
 T/C T/T 1.95 (0.64–5.91) 0.23 2.85 (0.64–12.59) 0.16
 T/T T/T 2.27 (0.79–6.50) 0.12 3.01 (0.73–12.32) 0.12
+894G>T polymorphism     
 T/T G/G 0.92 (0.21–3.98) 0.91
 T/G G/G 0.62 (0.21–1.82) 0.39
 G/G G/G 0.69 (0.26–1.84) 0.46
eNOS: Endothelial nitric oxide synthase; PCI: Percutaneous coronary intervention; OR: Odds ratio; CI: Confidence interval.
Table 6. Adjusted and unadjusted effects of potential predictors of the coronary slow-flow phenomenon after 
primary PCI
    Unadjusted Adjusted*
Risk factor OR (95% Cl) p value OR (95% Cl) p value
Platelet count 1.00 (0.99–1.00) 0.07 1.00 (0.99–1.00) 0.06
Blood sugar on admission 1.00 (1.00–1.01) 0.02 1.00 (0.99–1.01) 0.11
Hemoglobin level 0.70 (0.54–0.99) 0.04 0.71 (0.48–1.05) 0.08
PCI: Percutaneous coronary intervention; OR: Odds ratio; CI: Confidence interval.
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TIMI frame count.[29] Gupta et al.[37] reported a signif-
icant association between the 894G>T polymorphism 
and CSFP and reported a trend toward lower NO levels 
as the frequency of the T allele increased.
Several reasons can be cited for the lack of associ-
ation found in our study. For instance, 894G>T is not 
localized within the functional domain in the eNOS 
gene sequence,[45] which might cause the poor effect. 
Moreover, a meta-analysis by Rai et al.[43] showed that 
this diverse association between polymorphisms of 
the eNOS gene might be related to the variety of pop-
ulations and gene pools. Interestingly, 2 other Iranian 
studies did not find any association between NOS3 
polymorphisms and CAD.[51,52]
Apart from the association between the no-reflow 
phenomenon and CSFP and polymorphisms of the 
eNOS gene, several studies have endeavored to define 
the role of demographic and clinical characteristics in 
conjunction with procedural factors as independent 
predictors of this phenomenon after PPCI. Among the 
demographic characteristics, age,[14] female gender,[53] 
and cigarette smoking[43] were the most common risk 
factors allied to no-reflow/ CSFP. In our investigation, 
we found a lower prevalence rate of cigarette smoking 
in our patients with post-PCI CSFP. Chest pain dura-
tion has been proposed as an important predictor of 
the no-reflow phenomenon in multiple studies, which 
have demonstrated that a delayed presentation and an 
increased reperfusion time have a hazard ratio of 1.72 
(95% CI: 1.21–2.24; p=0.0024) and an OR of 13.84 
(95% CI: 3.21–59.63; p<0.001).(14) We, however, 
observed no significant effect regarding chest pain 
duration on the incidence of CSFP following PPCI. 
Ipek et al.[9] were the first to evaluate the power of 
the CHA2DS2-VASc score in predicting no-reflow/
CSFP. In our study, the CHA2DS2-VASc score was 
not a relevant estimator to predict CSFP in patients 
following PPCI. Several laboratory findings have 
been suggested as potential predictors of the no-reflow 
phenomenon in patients undergoing PPCI. Iwakura et 
al.[12] reported that the no-reflow phenomenon was 
more frequent in patients with a blood glucose level 
≥160 mg/dL than in those without hyperglycemia.. In-
triguingly, however, they found no difference in the 
incidence of diabetes mellitus between the 2 subsets. 
Likewise, we observed that our patients with CSFP 
after PPCI had significantly higher blood sugar lev-
els on admission. Adding to other reports, our results 
reduced NOS promoter activity by 50% and was as-
sociated with coronary spasm. Similarly, conflicting 
results have been published on the role of -786T>C: 
While some investigators have reported a strong rela-
tionship to the occurrence and severity of CAD,(10) 
others have arrived at no such conclusion.[40,47–49] Rai 
et al.,[43] in their systematic review of the association 
between polymorphisms of the eNOS gene and CAD, 
showed that ethnic variety influenced the effects of 
different SNPs on the risk of CAD. They found that 
894G>T had the strongest relationship in their Middle 
Eastern subgroup and -786T>C showed the highest as-
sociation with CAD among their population with Asian 
ancestry. As stated previously, in our study, the small 
number of patients (n=4) complicated by the no-reflow 
phenomenon (TIMI flow grade=0-1) rendered a statis-
tical analysis in this regard meaningless and forced us 
to compare the genetic variety of 2 of the most com-
mon eNOS SNPs (i.e., 894G>T and -786T>C) be-
tween patients with normal post-PPCI TIMI flow (≥3) 
and those with CSFP (post-PPCI TIMI flow ≤2). Our 
analysis indicated that the 894G>T polymorphism was 
not significantly associated with post-PPCI CSFP. Re-
garding the -786T>C polymorphism, our patients with 
the C/C genotype had a marginally significant risk of 
CSFP. This effect was not consistent in our adjusted 
analysis. To our knowledge, the existing literature con-
tains no investigation of the role of the polymorphisms 
of the eNOS gene in a PPCI setting. The majority of 
previous works have focused on the relationship in pa-
tients with stable CAD in whom CSFP was detected in 
coronary angiography. Even in this circumstance, how-
ever, mixed results have been reported on the associ-
ation between CSFP and polymorphisms of the eNOS 
gene. Gazi et al.[35] found that endothelial function was 
impaired in their patients with CSFP, but eNOS gene 
polymorphism (-786T>C) was not associated with 
CSFP. Caglayan et al.[50] reported the absence of an as-
sociation between the 894G>T polymorphism and T-
allele frequency of the eNOS gene and the presence of 
CSFP in a Turkish population. In contrast, Nurkalem 
et al.[36] reported an association between CSFP and the 
-786T>C polymorphism of the eNOS gene, in addition 
to a positive correlation between the TIMI frame count 
and the C allele. Ekmekci et al.[29] posited that the pres-
ence of the allele ‘a’ in intron 4a/b polymorphism of 
the eNOS gene might be a risk factor for microvascu-
lar endothelial dysfunction in patients with CSFP and 
reported that the allele ‘a’ was correlated with a higher 
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